101
|
Walker D, Li Y, Roxin Á, Schaffer P, Adam MJ, Perrin DM. Facile synthesis and 18F-radiolabeling of α 4β 1-specific LLP2A-aryltrifluoroborate peptidomimetic conjugates. Bioorg Med Chem Lett 2016; 26:5126-5131. [PMID: 27623550 DOI: 10.1016/j.bmcl.2016.08.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 08/04/2016] [Accepted: 08/05/2016] [Indexed: 12/11/2022]
Abstract
The peptidomimetic, LLP2A, is a specific, high-affinity ligand for α4β1 integrin receptors. Previously, several PEGylated LLP2A conjugates were evaluated in vivo as imaging agents for the detection of lymphoma, leukemia, multiple myeloma and melanoma tumours via NIR-fluorescence, 111In-SPECT, and 64Cu- and 68Ga-PET imaging. Despite these successes, to date there is no report of an 18F-labeled LLP2A conjugate. Notably, fluorine-18 is a preferred radionuclide for PET imaging, yet its short half-life and general inactivity under aqueous conditions present challenges for peptide labeling. A simple method for labeling complex biomolecules can be achieved with arylboronic acids that readily capture aqueous [18F]-fluoride ion resulting in an 18F-labeled aryltrifluoroborate ([18F]-ArBF3-) radioprosthetic group. Herein, we present the first radiosynthesis of an 18F-labeled LLP2A conjugate by both one-step 18F-labeling and one-pot two-step 18F-labeling post-'click' conjugation of the 18F-alkynyl-ArBF3- prosthetic. Competition with a fluorescent conjugate of LLP2A demonstrated specific binding of the non-radioactive isotopolog ArBF3--PEG2-LLP2A to α4β1 integrin-expressing MOLT-4 leukemia cells, as evidenced and confirmed by fluorescence microscopy. This work provides a key first step in the development of an expanding library of [18F]-R-BF3--LLP2A radiotracers for PET imaging.
Collapse
Affiliation(s)
- Daniel Walker
- Chemistry Department, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada
| | - Ying Li
- Chemistry Department, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada
| | - Áron Roxin
- Chemistry Department, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada
| | - Paul Schaffer
- Triumf, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada
| | - Michael J Adam
- Triumf, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada
| | - David M Perrin
- Chemistry Department, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada.
| |
Collapse
|
102
|
Perrin DM. [(18)F]-Organotrifluoroborates as Radioprosthetic Groups for PET Imaging: From Design Principles to Preclinical Applications. Acc Chem Res 2016; 49:1333-43. [PMID: 27054808 DOI: 10.1021/acs.accounts.5b00398] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Positron emission tomography (PET) is revolutionizing our ability to visualize in vivo targets for target validation and personalized medicine. Of several classes of imaging agents, peptides afford high affinity and high specificity to distinguish pathologically distinct cell types by the presence of specific molecular targets. Of various available PET isotopes, [(18)F]-fluoride ion is preferred because of its excellent nuclear properties and on-demand production in hospitals at Curie levels. However, the short half-life of (18)F and its lack of reactivity in water continue to challenge peptide labeling. Hence, peptides are often conjugated to a metal chelator for late-stage, one-step labeling. Yet radiometals, while effective, are neither as desirable nor as available as [(18)F]-fluoride ion. Despite considerable past success in identifying semifeasible radiosyntheses, significant challenges continue to confound tracer development. These interrelated challenges relate to (1) isotope/prosthetic choice; (2) bioconjugation for high affinity; (3) high radiochemical yields, (4) specific activities of >1 Ci/μmol to meet FDA microdose requirements; and (5) rapid clearance and in vivo stability. These enduring challenges have been extensively highlighted, while a single-step, operationally simple, and generally applicable means of labeling a peptide with [(18)F]-fluoride ion in good yield and high specific activity has eluded radiochemists and nuclear medicine practitioners for decades. Radiosynthetic ease is of primordial importance since multistep labeling reactions challenge clinical tracer production. In the past decade, as we sought to meet this challenge, appreciation of reactions with aqueous fluoride led us to consider organotrifluoroborate (RBF3(-)) synthesis as a means of rapid aqueous peptide labeling. We have applied principles of mechanistic chemistry, knowledge of chemical reactivity, and synthetic chemistry to design stable RBF3(-)s. Over the past 10 years, we have developed several new [(18)F]-RBF3(-) radioprosthetic groups, all of which guarantee radiosynthetic ease while in most cases providing high tumor:nontumor (T:NT) ratios and moderate-to-high tumor uptake. Although others have developed methods for labeling of peptides with [(18)F]-silylfluorides or [(18)F]-Al-NOTA chelates, this Account focuses on the synthesis of [(18)F]-organotrifluoroborates. In this Account, I detail mechanistic, kinetic, thermodynamic, synthetic, and radiosynthetic approaches that enabled the translation of fundamental principles regarding the chemistry of RBF3(-)s into a tantalizingly close realization of a clinical application of an [(18)F]-organotrifluoroborate-peptide conjugate for imaging of neuroendocrine tumors and the generalization of this method for labeling of several other peptides.
Collapse
Affiliation(s)
- David M. Perrin
- Chemistry Department, 2036 Main Mall, University of British Columbia, Vancouver, BC V6T 1Z1, Canada
| |
Collapse
|
103
|
Zhang Z, Amouroux G, Pan J, Jenni S, Zeisler J, Zhang C, Liu Z, Perrin DM, Bénard F, Lin KS. Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabel–Chelator Complex on Biodistribution and Tumor Uptake. Mol Pharm 2016; 13:2823-32. [DOI: 10.1021/acs.molpharmaceut.6b00428] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Zhengxing Zhang
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada
| | - Guillaume Amouroux
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada
| | - Jinhe Pan
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada
| | - Silvia Jenni
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada
| | - Jutta Zeisler
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada
| | - Chengcheng Zhang
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada
| | - Zhibo Liu
- Chemistry
Department, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - David M. Perrin
- Chemistry
Department, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - François Bénard
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada
- Department
of Radiology, University of British Columbia, Vancouver, British Columbia V5Z 4E3, Canada
| | - Kuo-Shyan Lin
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada
- Department
of Radiology, University of British Columbia, Vancouver, British Columbia V5Z 4E3, Canada
| |
Collapse
|
104
|
Chansaenpak K, Wang H, Wang M, Giglio B, Ma X, Yuan H, Hu S, Wu Z, Li Z. Synthesis and Evaluation of [(18) F]-Ammonium BODIPY Dyes as Potential Positron Emission Tomography Agents for Myocardial Perfusion Imaging. Chemistry 2016; 22:12122-9. [PMID: 27405398 DOI: 10.1002/chem.201601972] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Revised: 06/06/2016] [Indexed: 01/06/2023]
Abstract
Recently, we demonstrated the potential of a [(18) F]-trimethylammonium BODIPY dye for cardiac imaging. This is the first example of the use of the [(18) F]-ammonium BODIPY dye for positron emission tomography (PET) myocardial perfusion imaging (MPI). In this report, we extend our study to other ammonium BODIPY dyes with different nitrogen substituents. These novel ammonium BODIPY dyes were successfully prepared and radiolabeled by the SnCl4 -assisted (18) F-(19) F isotopic exchange method. The microPET results and the biodistribution data reveal that nitrogen substituent changes have a significant effect on the in vivo and pharmacological properties of the tracers. Of the novel [(18) F]-ammonium BODIPY dyes prepared in this work, the [(18) F]-dimethylethylammonium BODIPY is superior in terms of myocardium uptake and PET imaging contrast. These results support our hypothesis that the ammonium BODIPY dyes have a great potential for use as PET/optical dual-modality MPI probes.
Collapse
Affiliation(s)
- Kantapat Chansaenpak
- Biomedical Research Imaging Center, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, 27514, USA
| | - Hui Wang
- Biomedical Research Imaging Center, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, 27514, USA
| | - Mengzhe Wang
- Biomedical Research Imaging Center, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, 27514, USA
| | - Benjamin Giglio
- Biomedical Research Imaging Center, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, 27514, USA
| | - Xiaofeng Ma
- Biomedical Research Imaging Center, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, 27514, USA
| | - Hong Yuan
- Biomedical Research Imaging Center, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, 27514, USA
| | - Shuo Hu
- PET Center of Xiangya Hospital, Central South University, Changsha, 410008, China.
| | - Zhanhong Wu
- Biomedical Research Imaging Center, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, 27514, USA.
| | - Zibo Li
- Biomedical Research Imaging Center, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, 27514, USA
| |
Collapse
|
105
|
Abstract
Purpose [18F]VM4-037 was recently developed as a positron emission tomography (PET) tracer for the detection of carbonic anhydrase IX (CAIX), a tumor-specific protein upregulated under hypoxic conditions. In this study, the accumulation of [18F]VM4-037 was determined in two CAIX-expressing preclinical human tumor models. Procedures U373 and HT29 tumor-bearing animals were injected with [18F]VM4-037 and underwent microPET imaging up to 4 h post-injection (p.i.). Biodistribution throughout the different organs was assessed at 2 and 4 h p.i. using gamma counting. Results MicroPET imaging showed high [18F]VM4-037 uptake in the abdominal region, and biodistribution revealed high radioactivity in the kidney, ileum, colon, liver, stomach, and bladder. Although high CAIX expression was confirmed in both tumor models, tumor uptake assessed with microPET and biodistribution experiments was comparable to background tissues. Conclusions In this study, [18F]VM4-037 does not specifically accumulate in CAIX-expressing tumors, indicating that the tracer is not suitable for the detection of CAIX.
Collapse
|
106
|
Poschenrieder A, Osl T, Schottelius M, Hoffmann F, Wirtz M, Schwaiger M, Wester HJ. First 18F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo. ACTA ACUST UNITED AC 2016; 2:85-93. [PMID: 30042959 PMCID: PMC6024415 DOI: 10.18383/j.tom.2016.00130] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
In vivo quantification of CXCR4 expression using [68Ga]pentixafor for positron emission tomography (PET) imaging has gained significant clinical interest as CXCR4 plays a fundamental role in oncology and possesses potential prognostic value when overexpressed. To combine the excellent CXCR4-targeting properties of pentixafor-based tracers with the favorable radionuclide properties of 18F for high-resolution PET imaging, we developed an Al18F-labeled 1,4,7-triazacyclononane-triacetic acid (NOTA) analog of pentixather. Al18F-labeling of NOTA-pentixather was performed in aqueous dimethyl sulfoxide (DMSO) at pH = 4 (105°C, 15 minutes). CXCR4 affinities were determined in competitive binding assays, and both biodistribution and small-animal PET studies were performed in Daudi lymphoma-bearing mice. Under non-optimized conditions, [18F]AlF-NOTA-pentixather was obtained in radiochemical yields of 45.5% ± 13.3% and specific activities of up to 24.8 GBq/μmol. Compared with [natGa]pentixafor, [natF]AlF-NOTA-pentixather showed 1.4-fold higher CXCR4 affinity. [18F]AlF-NOTA-pentixather displayed high and CXCR4-specific in vivo uptake in Daudi xenografts (13.9% ± 0.8% injected dose per gram [ID/g] at 1 hour post injection [p.i.]). Because of its enhanced lipophilicity (logP = -1.4), [18F]AlF-NOTA-pentixather showed increased accumulation in the gall bladder and intestines. However, tumor/background ratios of 7.0 ± 1.2, 2.0 ± 0.3, 2.2 ± 0.4, 16.5 ± 6.5, and 29.2 ± 4 for blood, liver, small intestine, gut, and muscle, respectively, allowed for high-contrast visualization of Daudi tumors using PET (1 hour p.i.). The relatively straightforward radiosynthesis and efficient CXCR4 targeting of [18F]AlF-NOTA-pentixather demonstrate the successful implementation of 18F-complexation chemistry and pentixather-based CXCR4 targeting. Upon pharmacokinetic optimization, this class of tracers holds great promise for future application in humans.
Collapse
Affiliation(s)
| | - Theresa Osl
- Pharmaceutical Radiochemistry, Technische Universität München, Germany and
| | | | - Frauke Hoffmann
- Pharmaceutical Radiochemistry, Technische Universität München, Germany and
| | - Martina Wirtz
- Pharmaceutical Radiochemistry, Technische Universität München, Germany and
| | - Markus Schwaiger
- Nuklearmedizinische Klinik und Poliklinik, Technische Universität München, Ismaningerstr, München, Germany
| | - Hans-Jürgen Wester
- Pharmaceutical Radiochemistry, Technische Universität München, Germany and
| |
Collapse
|
107
|
Zhu J, Li S, Wängler C, Wängler B, Lennox RB, Schirrmacher R. Synthesis of 3-chloro-6-((4-(di-tert-butyl[(18)F]fluorosilyl)-benzyl)oxy)-1,2,4,5-tetrazine ([(18)F]SiFA-OTz) for rapid tetrazine-based (18)F-radiolabeling. Chem Commun (Camb) 2016; 51:12415-8. [PMID: 26145162 DOI: 10.1039/c5cc03623b] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
An efficient method to prepare the (18)F-labeled tetrazine-derivative [(18)F]-SiFA-OTz for bioorthogonal radiochemistry was developed. [(18)F]-SiFA-OTz can be synthesized with a radiochemical yield of 78 ± 5% within 25 min and can quantitatively react with a model strained dienophile, trans-cyclooctenol.
Collapse
Affiliation(s)
- Jun Zhu
- Department of Chemistry and Centre for Self-Assembled Chemical Structures, McGill University, 801 Sherbrooke St. West, Montreal, QC H3A 2K6, Canada.
| | | | | | | | | | | |
Collapse
|
108
|
Rodriguez EA, Wang Y, Crisp JL, Vera DR, Tsien RY, Ting R. New Dioxaborolane Chemistry Enables [(18)F]-Positron-Emitting, Fluorescent [(18)F]-Multimodality Biomolecule Generation from the Solid Phase. Bioconjug Chem 2016; 27:1390-1399. [PMID: 27064381 DOI: 10.1021/acs.bioconjchem.6b00164] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
New protecting group chemistry is used to greatly simplify imaging probe production. Temperature and organic solvent-sensitive biomolecules are covalently attached to a biotin-bearing dioxaborolane, which facilitates antibody immobilization on a streptavidin-agarose solid-phase support. Treatment with aqueous fluoride triggers fluoride-labeled antibody release from the solid phase, separated from unlabeled antibody, and creates [(18)F]-trifluoroborate-antibody for positron emission tomography and near-infrared fluorescent (PET/NIRF) multimodality imaging. This dioxaborolane-fluoride reaction is bioorthogonal, does not inhibit antigen binding, and increases [(18)F]-specific activity relative to solution-based radiosyntheses. Two applications are investigated: an anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibody (mAb) that labels prostate tumors and Cetuximab, an anti-epidermal growth factor receptor (EGFR) mAb (FDA approved) that labels lung adenocarcinoma tumors. Colocalized, tumor-specific NIRF and PET imaging confirm utility of the new technology. The described chemistry should allow labeling of many commercial systems, diabodies, nanoparticles, and small molecules for dual modality imaging of many diseases.
Collapse
Affiliation(s)
- Erik A Rodriguez
- Department of Pharmacology, University of California, San Diego, La Jolla, California 92093, United States
| | - Ye Wang
- Molecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, New York 10065, United States
| | - Jessica L Crisp
- Department of Pharmacology, University of California, San Diego, La Jolla, California 92093, United States
| | - David R Vera
- Department of Radiology, University of California, San Diego, La Jolla, California 92093, United States
| | - Roger Y Tsien
- Department of Pharmacology, University of California, San Diego, La Jolla, California 92093, United States.,Howard Hughes Medical Institute, La Jolla, California 92093, United States
| | - Richard Ting
- Department of Pharmacology, University of California, San Diego, La Jolla, California 92093, United States.,Molecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, New York 10065, United States
| |
Collapse
|
109
|
Zhang Z, Jenni S, Zhang C, Merkens H, Lau J, Liu Z, Perrin DM, Bénard F, Lin KS. Synthesis and evaluation of 18F-trifluoroborate derivatives of triphenylphosphonium for myocardial perfusion imaging. Bioorg Med Chem Lett 2016; 26:1675-9. [DOI: 10.1016/j.bmcl.2016.02.062] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2016] [Revised: 02/18/2016] [Accepted: 02/19/2016] [Indexed: 12/30/2022]
|
110
|
Liu Z, Chen X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem Soc Rev 2016; 45:1432-56. [PMID: 26771036 PMCID: PMC5227548 DOI: 10.1039/c5cs00158g] [Citation(s) in RCA: 282] [Impact Index Per Article: 35.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Albumin is the most abundant circulating protein in plasma and has recently emerged as a versatile protein carrier for drug targeting and for improving the pharmacokinetic profile of peptide or protein based drugs. Three drug delivery technologies related to albumin have been developed, which include the coupling of low-molecular weight drugs to exogenous or endogenous albumin, conjugating bioactive proteins by albumin fusion technology (AFT), and encapsulation of drugs into albumin nanoparticles. This review article starts with a brief introduction of human serum albumin (HSA), and then summarizes the mainstream chemical strategies of developing HSA binding molecules for coupling with drug molecules. Moreover, we also concisely condense the recent progress of the most important clinical applications of HSA-binding platforms, and specify the current challenges that need to be met for a bright future of HSA-binding.
Collapse
Affiliation(s)
- Zhibo Liu
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA.
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA.
| |
Collapse
|
111
|
Chansaenpak K, Wang M, Liu S, Wu Z, Yuan H, Conti PS, Li Z, Gabbaï FP. Synthesis and in vivo stability studies of [18F]-zwitterionic phosphonium aryltrifluoroborate/indomethacin conjugates. RSC Adv 2016. [DOI: 10.1039/c5ra26323a] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Conjugation of ortho-phosphonium phenyltrifluoroborates with indomethacin affords conjugates which have been radiolabeled by 18F–19F isotopic exchange in aqueous solutions and imaged by positron emission tomography in mice.
Collapse
Affiliation(s)
| | - Mengzhe Wang
- Department of Radiology
- Biomedical Research Imaging Center
- University of North Carolina
- Chapel Hill 27599
- USA
| | - Shuanglong Liu
- Molecular Imaging Center
- Department of Radiology
- University of Southern California
- Los Angeles 90033
- USA
| | - Zhanhong Wu
- Department of Radiology
- Biomedical Research Imaging Center
- University of North Carolina
- Chapel Hill 27599
- USA
| | - Hong Yuan
- Department of Radiology
- Biomedical Research Imaging Center
- University of North Carolina
- Chapel Hill 27599
- USA
| | - Peter S. Conti
- Molecular Imaging Center
- Department of Radiology
- University of Southern California
- Los Angeles 90033
- USA
| | - Zibo Li
- Department of Radiology
- Biomedical Research Imaging Center
- University of North Carolina
- Chapel Hill 27599
- USA
| | | |
Collapse
|
112
|
Bernard-Gauthier V, Bailey JJ, Liu Z, Wängler B, Wängler C, Jurkschat K, Perrin DM, Schirrmacher R. From Unorthodox to Established: The Current Status of (18)F-Trifluoroborate- and (18)F-SiFA-Based Radiopharmaceuticals in PET Nuclear Imaging. Bioconjug Chem 2015; 27:267-79. [PMID: 26566577 DOI: 10.1021/acs.bioconjchem.5b00560] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Unorthodox (18)F-labeling strategies not employing the formation of a carbon-(18)F bond are seldom found in radiochemistry. Historically, the formation of a boron- or silicon-(18)F bond has been introduced very early on into the repertoire of labeling chemistries, but is without translation into any clinical radiotracer besides inorganic B[(18)F]F4(-) for brain tumor diagnosis. For many decades these labeling methodologies were forgotten and have just recently been revived by a handful of researchers thinking outside the box. When breaking with established paradigms such as the inability to obtain labeled compounds of high specific activity via isotopic exchange or performing radiofluorination in aqueous media, the research community often reacts skeptically. In 2005 and 2006, two novel labeling methodologies were introduced into radiochemistry for positron emission tomography (PET) tracer development: RBF3(-) labeling reported by Perrin et al. and the SiFA methodology by Schirrmacher, Jurkschat, and Waengler et al. which is based on isotopic exchange (IE). Both labeling methodologies have been complemented by other noncanonical strategies to introduce (18)F into biomolecules of diagnostic importance, thus profoundly enriching the landscape of (18)F radiolabeling. B- and Si-based labeling strategies finally revealed that IE is a viable alternative to established and traditional radiochemistry with the advantage of simplifying both the labeling effort as well as the necessary purification of the radiotracer. Hence IE will be the focus of this contribution over other noncanonical labeling methods. Peptides for tumor imaging especially lend themselves favorably toward one-step labeling via IE, but small molecules have been described as well, taking advantage of these new approaches, and have been used successfully for brain imaging. This Review gives an account of both radiochemistries centered on boron and silicon, describing the very beginnings of their basic research, the path that led to optimization of their chemistries, and the first encouraging preclinical results paving the way to their clinical use. This side by side approach will give the reader the opportunity to follow the development of a new basic discovery into a clinically applicable radiotracer including all the hurdles that have had to be overcome.
Collapse
Affiliation(s)
- Vadim Bernard-Gauthier
- Division of Oncological Imaging, Department of Oncology, University of Alberta , 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada
| | - Justin J Bailey
- Division of Oncological Imaging, Department of Oncology, University of Alberta , 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada
| | - Zhibo Liu
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health , 9000 Rockville Pike, Bethesda, Maryland 20892, United States
| | | | | | - Klaus Jurkschat
- Department of Chemistry and Chemical Biology, Technical University of Dortmund , 44227 Dortmund, Germany
| | - David M Perrin
- Department of Chemistry, University of British Columbia , 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada
| | - Ralf Schirrmacher
- Division of Oncological Imaging, Department of Oncology, University of Alberta , 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada
| |
Collapse
|
113
|
Chansaenpak K, Vabre B, Gabbaï FP. [(18)F]-Group 13 fluoride derivatives as radiotracers for positron emission tomography. Chem Soc Rev 2015; 45:954-71. [PMID: 26548467 DOI: 10.1039/c5cs00687b] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The field of (18)F chemistry is rapidly expanding because of the use of this radionuclide in radiotracers for positron emission tomography (PET). Until recently, most [(18)F]-radiotracers were generated by the direct attachment of (18)F to a carbon in the organic backbone of the radiotracer. The past decade has witnessed the emergence of a new strategy based on the formation of an (18)F-group 13 element bond. This approach, which is rooted in the field of fluoride anion complexation/coordination chemistry, has led to the development of a remarkable family of boron, aluminium and gallium [(18)F]-fluoride anion complexing agents which can be conjugated with peptides and small molecules to generate disease specific PET radiotracers. This review is dedicated to the chemistry of these group 13 [(18)F]-fluorides anion complexing agents and their use in PET. Some of the key fluoride-binding motifs covered in this review include the trifluoroborate unit bound to neutral or cationic electron deficient backbones, the BF2 unit of BODIPY dyes, and AlF or GaF3 units coordinated to multidentate Lewis basic ligands. In addition to describing how these moieties can be converted into their [(18)F]-analogs, this review also dicusses their incorporation into bioconjugates for application in PET.
Collapse
Affiliation(s)
- Kantapat Chansaenpak
- Department of Chemistry, Texas A&M University, College Station, Texas 77843, USA.
| | | | | |
Collapse
|
114
|
Liu Q, Pan D, Cheng C, Zhang D, Zhang A, Wang L, Jiang H, Wang T, Liu H, Xu Y, Yang R, Chen F, Yang M, Zuo C. Development of a Novel PET Tracer [18F]AlF-NOTA-C6 Targeting MMP2 for Tumor Imaging. PLoS One 2015; 10:e0141668. [PMID: 26540114 PMCID: PMC4634933 DOI: 10.1371/journal.pone.0141668] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2014] [Accepted: 10/12/2015] [Indexed: 12/28/2022] Open
Abstract
Background and Objective The overexpression of gelatinases, that is, matrix metalloproteinase MMP2 and MMP9, has been associated with tumor progression, invasion, and metastasis. To image MMP2 in tumors, we developed a novel ligand termed [18F]AlF-NOTA-C6, with consideration that: c(KAHWGFTLD)NH2 (herein, C6) is a selective gelatinase inhibitor; Cy5.5-C6 has been visualized in many in vivo tumor models; positron emission tomography (PET) has a higher detection sensitivity and a wider field of view than optical imaging; fluorine-18 (18F) is the optimal PET radioisotope, and the creation of a [18F]AlF-peptide complex is a simple procedure. Methods C6 was conjugated to the bifunctional chelator NOTA (1, 4, 7-triazacyclononanetriacetic acid) for radiolabeling [18F]AlF conjugation. The MMP2-binding characteristics and tumor-targeting efficacy of [18F]AlF-NOTA-C6 were tested in vitro and in vivo. Results The non-decay corrected yield of [18F]AlF-NOTA-C6 was 46.2–64.2%, and the radiochemical purity exceeded 95%. [18F]AlF-NOTA-C6 was favorably retained in SKOV3 and PC3 cells, determined by cell uptake. Using NOTA-C6 as a competitive ligand, the uptake of [18F]AlF-NOTA-C6 in SKOV3 cells decreased in a dose-dependent manner. In biodistribution and PET imaging studies, higher radioactivity concentrations were observed in tumors. Pre-injection of C6 caused a marked reduction in tumor tissue uptake. Immunohistochemistry showed MMP2 in tumor tissues. Conclusions [18F]AlF-NOTA-C6 was easy to synthesize and has substantial potential as an imaging agent that targets MMP2 in tumors.
Collapse
Affiliation(s)
- Qinghua Liu
- Department of Nuclear Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, 200433, China
- * E-mail: (QHL); (MY); (CJZ)
| | - Donghui Pan
- Jiangsu Institute of Nuclear Medicine, Key Laboratory of Nuclear Medicine, Ministry of Health, Wuxi, 214063, China
| | - Chao Cheng
- Department of Nuclear Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, 200433, China
| | - Dazhi Zhang
- Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China
| | - Anyu Zhang
- Department of Nuclear Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, 200433, China
| | - Lizhen Wang
- Jiangsu Institute of Nuclear Medicine, Key Laboratory of Nuclear Medicine, Ministry of Health, Wuxi, 214063, China
| | - Hongdie Jiang
- Department of Nuclear Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, 200433, China
| | - Tao Wang
- Department of Nuclear Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, 200433, China
| | - Hongrui Liu
- Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, 201203, China
| | - Yuping Xu
- Jiangsu Institute of Nuclear Medicine, Key Laboratory of Nuclear Medicine, Ministry of Health, Wuxi, 214063, China
| | - Runlin Yang
- Jiangsu Institute of Nuclear Medicine, Key Laboratory of Nuclear Medicine, Ministry of Health, Wuxi, 214063, China
| | - Fei Chen
- Jiangsu Institute of Nuclear Medicine, Key Laboratory of Nuclear Medicine, Ministry of Health, Wuxi, 214063, China
| | - Min Yang
- Jiangsu Institute of Nuclear Medicine, Key Laboratory of Nuclear Medicine, Ministry of Health, Wuxi, 214063, China
- * E-mail: (QHL); (MY); (CJZ)
| | - Changjing Zuo
- Department of Nuclear Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, 200433, China
- * E-mail: (QHL); (MY); (CJZ)
| |
Collapse
|
115
|
Wang L, Jacobson O, Avdic D, Rotstein BH, Weiss ID, Collier L, Chen X, Vasdev N, Liang SH. Ortho-Stabilized (18) F-Azido Click Agents and their Application in PET Imaging with Single-Stranded DNA Aptamers. Angew Chem Int Ed Engl 2015; 54:12777-81. [PMID: 26308650 PMCID: PMC4698351 DOI: 10.1002/anie.201505927] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Indexed: 12/20/2022]
Abstract
Azido (18) F-arenes are important and versatile building blocks for the radiolabeling of biomolecules via Huisgen cycloaddition ("click chemistry") for positron emission tomography (PET). However, routine access to such clickable agents is challenged by inefficient and/or poorly defined multistep radiochemical approaches. A high-yielding direct radiofluorination for azido (18) F-arenes was achieved through the development of an ortho-oxygen-stabilized iodonium derivative (OID). This OID strategy addresses an unmet need for a reliable azido (18) F-arene clickable agent for bioconjugation reactions. A ssDNA aptamer was radiolabeled with this agent and visualized in a xenograft mouse model of human colon cancer by PET, which demonstrates that this OID approach is a convenient and highly efficient way of labeling and tracking biomolecules.
Collapse
Affiliation(s)
- Lu Wang
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114 (USA)
| | - Orit Jacobson
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892 (USA)
| | - Din Avdic
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114 (USA)
| | - Benjamin H Rotstein
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114 (USA)
| | - Ido D Weiss
- Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 (USA)
| | - Lee Collier
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114 (USA)
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892 (USA).
| | - Neil Vasdev
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114 (USA).
| | - Steven H Liang
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114 (USA).
| |
Collapse
|
116
|
Litau S, Niedermoser S, Vogler N, Roscher M, Schirrmacher R, Fricker G, Wängler B, Wängler C. Next Generation of SiFAlin-Based TATE Derivatives for PET Imaging of SSTR-Positive Tumors: Influence of Molecular Design on In Vitro SSTR Binding and In Vivo Pharmacokinetics. Bioconjug Chem 2015; 26:2350-9. [PMID: 26420336 DOI: 10.1021/acs.bioconjchem.5b00510] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The Silicon-Fluoride-Acceptor (SiFA)-(18)F-labeling strategy has been shown before to enable the straightforward and efficient (18)F-labeling of complex biologically active substances such as proteins and peptides. Especially in the case of peptides, the radiolabeling proceeds kit-like in short reaction times and without the need of complex product workup. SiFA-derivatized, (18)F-labeled Tyr(3)-octreotate (TATE) derivatives demonstrated, besides strong somatostatin receptor (SSTR) binding, favorable in vivo pharmacokinetics as well as excellent tumor visualization by PET imaging. In this study, we intended to determine the influence of the underlying molecular design and used molecular scaffolds of SiFAlin-TATE derivatives on SSTR binding as well as on the in vivo pharmacokinetics of the resulting (18)F-labeled peptides. For this purpose, new SiFAlin-(Asp)n-PEG1-TATE analogs (where n = 1-4) were synthesized, efficiently radiolabeled with (18)F in a kit-like manner and obtained in radiochemical yields of 70-80%, radiochemical purities of ≥97%, and nonoptimized specific activities of 20.1-45.2 GBq/μmol within 20-25 min starting from 0.7-1.5 GBq of (18)F. In the following, the radiotracer's lipophilicities and stabilities in human serum were determined. Furthermore, the SSTR-specific binding affinities were evaluated by a competitive displacement assay on SSTR-positive AR42J cells. The obtained in vitro results support the assumption that aspartic acids are able to considerably increase the radiotracer's hydrophilicity and that their number does not affect the SSTR binding potential of the TATE derivatives. The most promising tracer (18)F-SiFAlin-Asp3-PEG1-TATE [(18)F]6 (LogD = -1.23 ± 0.03, IC50 = 20.7 ± 2.5 nM) was further evaluated in vivo in AR42J tumor-bearing nude mice via PET/CT imaging against the clinical gold standard (68)Ga-DOTATATE as well as the previously developed SiFAlin-TATE derivative [(18)F]3. The results of these evaluations showed that [(18)F]6-although showing very similar chemical and in vitro properties to [(18)F]3-exhibits not only a slowed renal clearance compared to [(18)F]3, but also a higher absolute tumor uptake compared to (68)Ga-DOTATATE, and furthermore enables excellent tumor visualization with high image resolution. These results emphasize the importance of systematic study of the influence of molecular design and applied structure elements of peptidic radiotracers, as these may considerably influence in vivo pharmacokinetics while not affecting other parameters such as radiochemistry, lipophilicity, serum stability, or receptor binding potential.
Collapse
Affiliation(s)
| | | | | | | | - R Schirrmacher
- Department of Oncology, Division of Oncological Imaging, University of Alberta , Edmonton T6G 2R3, Canada
| | - G Fricker
- Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg , 69117 Heidelberg, Germany
| | | | | |
Collapse
|
117
|
Liu Z, Lin KS, Bénard F, Pourghiasian M, Kiesewetter DO, Perrin DM, Chen X. One-step (18)F labeling of biomolecules using organotrifluoroborates. Nat Protoc 2015; 10:1423-32. [PMID: 26313478 PMCID: PMC5223096 DOI: 10.1038/nprot.2015.090] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Herein we present a general protocol for the functionalization of biomolecules with an organotrifluoroborate moiety so that they can be radiolabeled with aqueous (18)F fluoride ((18)F(-)) and used for positron emission tomography (PET) imaging. Among the β(+)-emitting radionuclides, fluorine-18 ((18)F) is the isotope of choice for PET, and it is produced, on-demand, in many hospitals worldwide. Organotrifluoroborates can be (18)F-labeled in one step in aqueous conditions via (18)F-(19)F isotope exchange. This protocol features a recently designed ammoniomethyltrifluoroborate, and it describes the following: (i) a synthetic strategy that affords modular synthesis of radiolabeling precursors via a copper-catalyzed 'click' reaction; and (ii) a one-step (18)F-labeling method that obviates the need for HPLC purification. Within 30 min, (18)F-labeled PET imaging probes, such as peptides, can be synthesized in good chemical and radiochemical purity (>98%), satisfactory radiochemical yield of 20-35% (n > 20, non-decay corrected) and high specific activity of 40-111 GBq/μmol (1.1-3.0 Ci/μmol). The entire procedure, including the precursor preparation and (18)F radiolabeling, takes 7-10 d.
Collapse
Affiliation(s)
- Zhibo Liu
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA
| | - Kuo-Shyan Lin
- Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - François Bénard
- Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Maral Pourghiasian
- Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Dale O Kiesewetter
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA
| | - David M Perrin
- Department of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
118
|
Liu Z, Chen H, Chen K, Shao Y, Kiesewetter DO, Niu G, Chen X. Boramino acid as a marker for amino acid transporters. SCIENCE ADVANCES 2015; 1:e1500694. [PMID: 26601275 PMCID: PMC4643766 DOI: 10.1126/sciadv.1500694] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Accepted: 07/08/2015] [Indexed: 06/05/2023]
Abstract
Amino acid transporters (AATs) are a series of integral channels for uphill cellular uptake of nutrients and neurotransmitters. Abnormal expression of AATs is often associated with cancer, addiction, and multiple mental diseases. Although methods to evaluate in vivo expression of AATs would be highly useful, efforts to develop them have been hampered by a lack of appropriate tracers. We describe a new class of AA mimics-boramino acids (BAAs)-that can serve as general imaging probes for AATs. The structure of a BAA is identical to that of the corresponding natural AA, except for an exotic replacement of the carboxylate with -BF3 (-). Cellular studies demonstrate strong AAT-mediated cell uptake, and animal studies show high tumor-specific accumulation, suggesting that BAAs hold great promise for the development of new imaging probes and smart AAT-targeting drugs.
Collapse
Affiliation(s)
- Zhibo Liu
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health (NIH), Bethesda, MD 20892, USA
| | - Haojun Chen
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health (NIH), Bethesda, MD 20892, USA
- Department of nuclear medicine, Xiamen Cancer Center, First Affiliated Hospital of Xiamen University, Xiamen 361003, China
| | - Kai Chen
- Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| | - Yihan Shao
- Laboratory of Computational Biology, National Heart Lung and Blood Institute, NIH, Bethesda, MD 20892, USA
| | - Dale O. Kiesewetter
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health (NIH), Bethesda, MD 20892, USA
| | - Gang Niu
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health (NIH), Bethesda, MD 20892, USA
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health (NIH), Bethesda, MD 20892, USA
| |
Collapse
|
119
|
Wang L, Jacobson O, Avdic D, Rotstein BH, Weiss ID, Collier L, Chen X, Vasdev N, Liang SH. Ortho-Stabilized18F-Azido Click Agents and their Application in PET Imaging with Single-Stranded DNA Aptamers. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201505927] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
120
|
Chansaenpak K, Wang M, Wu Z, Zaman R, Li Z, Gabbaï FP. [(18)F]-NHC-BF3 adducts as water stable radio-prosthetic groups for PET imaging. Chem Commun (Camb) 2015; 51:12439-12442. [PMID: 26144217 PMCID: PMC5457534 DOI: 10.1039/c5cc04545b] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The radiofluorination of N-heterocyclic carbene (NHC) boron trifluoride adducts affords novel [(18)F]-positron emission tomography probes which resist hydrolytic fluoride release. The labelling protocol relies on an (18)F-(19)F isotopic exchange reaction promoted by the Lewis acid SnCl4. Modification of the NHC backbone with a maleimide functionality provides access to a model peptide conjugate which shows no evidence of defluorination when imaged in vivo.
Collapse
Affiliation(s)
- Kantapat Chansaenpak
- Department of Chemistry, Texas A&M University, College Station, Texas 77843, USA.
| | - Mengzhe Wang
- Department of Radiology, Biomedical Research Imaging Center, University of North Carolina, Chapel Hill 27599, USA.
| | - Zhanhong Wu
- Department of Radiology, Biomedical Research Imaging Center, University of North Carolina, Chapel Hill 27599, USA.
| | - Rehmat Zaman
- Department of Chemistry, Texas A&M University, College Station, Texas 77843, USA.
| | - Zibo Li
- Department of Radiology, Biomedical Research Imaging Center, University of North Carolina, Chapel Hill 27599, USA.
| | - François P Gabbaï
- Department of Chemistry, Texas A&M University, College Station, Texas 77843, USA.
| |
Collapse
|
121
|
Lau J, Liu Z, Lin KS, Pan J, Zhang Z, Vullo D, Supuran CT, Perrin DM, Bénard F. Trimeric Radiofluorinated Sulfonamide Derivatives to Achieve In Vivo Selectivity for Carbonic Anhydrase IX–Targeted PET Imaging. J Nucl Med 2015. [DOI: 10.2967/jnumed.114.153288] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
122
|
|
123
|
Preise 2015 der Canadian Society for Chemistry. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201504360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
124
|
Zeng JL, Wang J, Ma JA. New strategies for rapid (18)F-radiolabeling of biomolecules for radionuclide-based in vivo imaging. Bioconjug Chem 2015; 26:1000-3. [PMID: 25898224 DOI: 10.1021/acs.bioconjchem.5b00180] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The increasing availability of highly active no-carrier-added [(18)F]-fluoride makes its use in radiolabeling biomolecules attractive. By incorporating "fluorophilic" elements (Si, B, and Al) into biomolecules, recent advances offer mild and rapid (18)F-labeling approaches without HPLC purification at the radiosynthetic stage while maintaining sufficient specific activity. In this Topical Review, we will discuss the most recent strides in the field.
Collapse
Affiliation(s)
- Jun-Liang Zeng
- †Department of Chemistry, Key Laboratory of Systems Bioengineering (the Ministry of Education), Tianjin University, and Collaborative Innovation Center of Chemical Science and Engineering, Tianjin 300072, P. R. China
| | - Jian Wang
- ‡Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, P. R. China
| | - Jun-An Ma
- †Department of Chemistry, Key Laboratory of Systems Bioengineering (the Ministry of Education), Tianjin University, and Collaborative Innovation Center of Chemical Science and Engineering, Tianjin 300072, P. R. China
| |
Collapse
|
125
|
Pourghiasian M, Liu Z, Pan J, Zhang Z, Colpo N, Lin KS, Perrin DM, Bénard F. 18F-AmBF3-MJ9: A novel radiofluorinated bombesin derivative for prostate cancer imaging. Bioorg Med Chem 2015; 23:1500-6. [DOI: 10.1016/j.bmc.2015.02.009] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Revised: 01/29/2015] [Accepted: 02/06/2015] [Indexed: 12/11/2022]
|
126
|
Liu Z, Amouroux G, Zhang Z, Pan J, Hundal-Jabal N, Colpo N, Lau J, Perrin DM, Bénard F, Lin KS. 18F-Trifluoroborate Derivatives of [Des-Arg10]Kallidin for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography. Mol Pharm 2015; 12:974-82. [DOI: 10.1021/acs.molpharmaceut.5b00003] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Zhibo Liu
- Chemistry
Department, University of British Columbia, Vancouver, BC V6T 1Z1, Canada
| | - Guillaume Amouroux
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada
| | - Zhengxing Zhang
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada
| | - Jinhe Pan
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada
| | - Navjit Hundal-Jabal
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada
| | - Nadine Colpo
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada
| | - Joseph Lau
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada
| | - David M. Perrin
- Chemistry
Department, University of British Columbia, Vancouver, BC V6T 1Z1, Canada
| | - François Bénard
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada
- Department
of Radiology, University of British Columbia, Vancouver, BC V5Z 4E3, Canada
| | - Kuo-Shyan Lin
- Department
of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada
- Department
of Radiology, University of British Columbia, Vancouver, BC V5Z 4E3, Canada
| |
Collapse
|
127
|
Liu Z, Chao D, Li Y, Ting R, Oh J, Perrin DM. From Minutes to Years: Predicting Organotrifluoroborate Solvolysis Rates. Chemistry 2015; 21:3924-8. [DOI: 10.1002/chem.201405829] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Indexed: 01/22/2023]
|
128
|
Richter S, Wuest F. 18F-Labeled Peptides: The Future Is Bright. Molecules 2014; 19:20536-20556. [PMID: 25493636 PMCID: PMC6271677 DOI: 10.3390/molecules191220536] [Citation(s) in RCA: 92] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Revised: 11/24/2014] [Accepted: 11/28/2014] [Indexed: 01/10/2023] Open
Abstract
Radiolabeled peptides have been the subject of intense research efforts for targeted diagnostic imaging and radiotherapy over the last 20 years. Peptides offer several advantages for receptor imaging and targeted radiotherapy. The low molecular weight of peptides allows for rapid clearance from the blood and non-target tissue, which results in favorable target-to-non-target ratios. Moreover, peptides usually display good tissue penetration and they are generally non-immunogenic. A major drawback is their potential low metabolic stability. The majority of currently used radiolabeled peptides for targeted molecular imaging and therapy of cancer is labeled with various radiometals like 99mTc, 68Ga, and 177Lu. However, over the last decade an increasing number of 18F-labeled peptides have been reported. Despite of obvious advantages of 18F like its ease of production in large quantities at high specific activity, the low β+ energy (0.64 MeV) and the favorable half-life (109.8 min), 18F-labeling of peptides remains a special challenge. The first part of this review will provide a brief overview on chemical strategies for peptide labeling with 18F. A second part will discuss recent technological advances for 18F-labeling of peptides with special focus on microfluidic technology, automation, and kit-like preparation of 18F-labeled peptides.
Collapse
Affiliation(s)
- Susan Richter
- Department of Oncology, University of Alberta, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada.
| | - Frank Wuest
- Department of Oncology, University of Alberta, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada.
| |
Collapse
|